BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, Ayuso C, Vargas V, Rodés J, Bruix J. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology. 2000;31:54-58. [PMID: 10613728 DOI: 10.1002/hep.510310111] [Cited by in Crossref: 179] [Cited by in F6Publishing: 163] [Article Influence: 8.1] [Reference Citation Analysis]
Number Citing Articles
1 Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015;12:681-700. [PMID: 26484443 DOI: 10.1038/nrgastro.2015.173] [Cited by in Crossref: 252] [Cited by in F6Publishing: 262] [Article Influence: 36.0] [Reference Citation Analysis]
2 Zhong C, Li Y, Yang J, Jin S, Chen G, Li D, Fan X, Lin H. Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects. Front Oncol 2021;11:589680. [PMID: 33854960 DOI: 10.3389/fonc.2021.589680] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Rui JA, Wang SB, Chen SG, Zhou L. Right trisectionectomy for primary liver cancer. World J Gastroenterol. 2003;9:706-709. [PMID: 12679915 DOI: 10.1016/s1091-255x(02)00267-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
4 Di Maio M, De Maio E, Perrone F, Pignata S, Daniele B. Hepatocellular Carcinoma: Systemic Treatments. Journal of Clinical Gastroenterology 2002;35:S109-14. [DOI: 10.1097/00004836-200211002-00007] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 2.1] [Reference Citation Analysis]
5 de Luján Alvarez M, Cerliani JP, Monti J, Carnovale C, Ronco MT, Pisani G, Lugano MC, Carrillo MC. The in vivo apoptotic effect of interferon alfa-2b on rat preneoplastic liver involves Bax protein. Hepatology 2002;35:824-33. [PMID: 11915028 DOI: 10.1053/jhep.2002.32099] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
6 Matsumoto K, Okano J, Murawaki Y. Differential effects of interferon alpha-2b and beta on the signaling pathways in human liver cancer cells. J Gastroenterol 2005;40:722-32. [DOI: 10.1007/s00535-005-1616-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
7 Burroughs A, Hochhauser D, Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. The Lancet Oncology 2004;5:409-18. [DOI: 10.1016/s1470-2045(04)01508-6] [Cited by in Crossref: 117] [Cited by in F6Publishing: 44] [Article Influence: 6.5] [Reference Citation Analysis]
8 Vera MC, Lorenzetti F, Lucci A, Comanzo CG, Ceballos MP, Pisani GB, Alvarez MDL, Quiroga AD, Carrillo MC. Vitamin K2 supplementation blocks the beneficial effects of IFN-α-2b administered on the early stages of liver cancer development in rats. Nutrition 2019;59:170-9. [DOI: 10.1016/j.nut.2018.08.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Bricard G, Bouzourene H, Martinet O, Rimoldi D, Halkic N, Gillet M, Chaubert P, Macdonald HR, Romero P, Cerottini J, Speiser DE. Naturally Acquired MAGE-A10- and SSX-2-Specific CD8 + T Cell Responses in Patients with Hepatocellular Carcinoma. J Immunol 2005;174:1709-16. [DOI: 10.4049/jimmunol.174.3.1709] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 4.1] [Reference Citation Analysis]
10 Wu MY, Yiang GT, Cheng PW, Chu PY, Li CJ. Molecular Targets in Hepatocarcinogenesis and Implications for Therapy. J Clin Med. 2018;7. [PMID: 30104473 DOI: 10.3390/jcm7080213] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
11 Wu J, Huang WJ, Wang HY, Wang YF, Peng BG, Zhou Q. Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus. Med Oncol 2015;32:65. [PMID: 25691293 DOI: 10.1007/s12032-015-0491-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat. 2010;17:287-292. [PMID: 19732321 DOI: 10.1111/j.1365-2893.2009.01181.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 5.7] [Reference Citation Analysis]
13 Pang RW, Poon RT. Clinical implications of angiogenesis in cancers. Vasc Health Risk Manag. 2006;2:97-108. [PMID: 17319453 DOI: 10.2147/vhrm.2006.2.2.97] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
14 Hong YP, Li ZD, Prasoon P, Zhang Q. Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. World J Hepatol 2015; 7(7): 980-992 [PMID: 25954480 DOI: 10.4254/wjh.v7.i7.980] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
15 Palmer DH, Hussain SA, Johnson PJ. Systemic therapies for hepatocellular carcinoma. Expert Opin Investig Drugs. 2004;13:1555-1568. [PMID: 15566313 DOI: 10.1517/13543784.13.12.1555] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
16 Jesus VHF, Felismino TC, Barros E Silva MJ, Souza E Silva V, Riechelmann RP. Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies. Clinics (Sao Paulo) 2018;73:e510s. [PMID: 30365605 DOI: 10.6061/clinics/2018/e510s] [Reference Citation Analysis]
17 Ruff P. Therapeutic Options in Hepatocellular Carcinoma: . American Journal of Cancer 2004;3:119-31. [DOI: 10.2165/00024669-200403020-00004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Bharadwaj M, Roy G, Dutta K, Misbah M, Husain M, Hussain S. Tackling hepatitis B virus-associated hepatocellular carcinoma--the future is now. Cancer Metastasis Rev. 2013;32:229-268. [PMID: 23114844 DOI: 10.1007/s10555-012-9412-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
19 Han KH, Park JY. Systemic treatment in advanced/metastatic hepatocellular carcinoma in the era of targeted therapy. J Gastroenterol Hepatol 2010;25:1023-5. [PMID: 20594213 DOI: 10.1111/j.1440-1746.2010.06359.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
20 Tabor E. Interferon for preventing and treating hepatocellular carcinoma associated with the hepatitis B and C viruses. Dig Liver Dis 2003;35:297-305. [PMID: 12846400 DOI: 10.1016/s1590-8658(03)00071-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
21 Zhou C, Yu Q, Chen L, Wang J, Zheng S, Zhang J. A miR-1231 binding site polymorphism in the 3’UTR of IFNAR1 is associated with hepatocellular carcinoma susceptibility. Gene. 2012;507:95-98. [PMID: 22824466 DOI: 10.1016/j.gene.2012.06.073] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
22 Hourmand-Ollivier I, Chiche L. [Treatment of hepatocellular carcinoma in the cirrhotic liver]. J Chir (Paris) 2004;141:71-83. [PMID: 15133430 DOI: 10.1016/s0021-7697(04)95574-3] [Reference Citation Analysis]
23 Cabibbo G, Antonucci M, Genco C. Update on new approaches in the management of hepatocellular carcinoma. Hepat Med 2010;2:163-73. [PMID: 24367214 DOI: 10.2147/HMER.S7132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
24 Cheung TT, Kwok PC, Chan S, Cheung CC, Lee AS, Lee V, Cheng HC, Chia NH, Chong CCN, Lai TW, Law ALY, Luk MY, Tong CC, Yau TCC. Hong Kong Consensus Statements for the Management of Unresectable Hepatocellular Carcinoma. Liver Cancer 2018;7:40-54. [PMID: 29662832 DOI: 10.1159/000485984] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
25 Ikeda M, Mitsunaga S, Ohno I, Hashimoto Y, Takahashi H, Watanabe K, Umemoto K, Okusaka T. Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future. Diseases 2015;3:360-81. [PMID: 28943630 DOI: 10.3390/diseases3040360] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
26 Wongcharatrawee S, Groszmann RJ. Diagnosing portal hypertension. Best Practice & Research Clinical Gastroenterology 2000;14:881-94. [DOI: 10.1053/bega.2000.0136] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
27 Morimoto M, Numata K, Nozaki A, Tanaka K. Prognosis following non-surgical second treatment in patients with recurrent hepatocellular carcinoma after percutaneous ablation therapy. Liver International 2009;29:443-8. [DOI: 10.1111/j.1478-3231.2008.01890.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
28 Zhuang L, Zeng X, Yang Z, Meng Z. Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2013;8:e61361. [PMID: 24069133 DOI: 10.1371/journal.pone.0061361] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
29 Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012;6:207-19. [PMID: 22904613 DOI: 10.2147/BTT.S23907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 27] [Article Influence: 0.5] [Reference Citation Analysis]
30 Kuyvenhoven JPh CB, van Hoek B. Practical management of hepatocellular carcinoma. Scand J Gastroenterol Suppl. 2001;234:82-87. [PMID: 11768566 DOI: 10.1080/003655201753265154] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
31 Du W, Xu Z, Ma X, Song L, Schneider E. Biochip as a potential platform of serological interferon α2b antibody assay. Journal of Biotechnology 2003;106:87-100. [DOI: 10.1016/j.jbiotec.2003.08.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
32 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2003; 11(9): 1416-1419 [DOI: 10.11569/wcjd.v11.i9.1416] [Reference Citation Analysis]
33 Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW, Weitz J. Hepatocellular Carcinoma: Current Management and Perspectives for the Future. Annals of Surgery 2011;253:453-69. [DOI: 10.1097/sla.0b013e31820d944f] [Cited by in Crossref: 282] [Cited by in F6Publishing: 170] [Article Influence: 25.6] [Reference Citation Analysis]
34 Zhang G, Wang Q, Xu R. Therapeutics Based on microRNA: A New Approach for Liver Cancer. Curr Genomics 2010;11:311-25. [PMID: 21286309 DOI: 10.2174/138920210791616671] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
35 Merle P, Barraud L, Lefrançois L, Chevallier M, Guerret S, Maisonnas M, Bordes I, Savre-Train I, Trepo C, Vitvitski-Trepo L. Long-term high-dose interferon-alpha therapy delays Hepadnavirus-related hepatocarcinogenesis in X/myc transgenic mice. Oncogene 2003;22:2762-71. [PMID: 12743599 DOI: 10.1038/sj.onc.1206375] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
36 Nagano H, Wada H, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, Tomimaru Y, Osuga K, Umeshita K, Doki Y. Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology. 2011;80:63-69. [PMID: 21659784 DOI: 10.1159/000328281] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
37 Nushtaeva AA, Stepanov GA, Semenov DV, Juravlev ES, Balahonova EA, Gerasimov AV, Sidorov SV, Savelyev EI, Kuligina EV, Richter VA, Koval OA. Characterization of primary normal and malignant breast cancer cell and their response to chemotherapy and immunostimulatory agents. BMC Cancer 2018;18:728. [PMID: 29986702 DOI: 10.1186/s12885-018-4635-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
38 Lewandowski RJ, Tepper J, Wang D, Ibrahim S, Miller FH, Kulik L, Mulcahy M, Ryu RK, Sato K, Larson AC, Salem R, Omary RA. MR Imaging Perfusion Mismatch: A Technique to Verify Successful Targeting of Liver Tumors during Transcatheter Arterial Chemoembolization. Journal of Vascular and Interventional Radiology 2008;19:698-705. [DOI: 10.1016/j.jvir.2008.01.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
39 Takaki-Hamabe S, Yamasaki T, Saeki I, Harima Y, Okita K, Terai S, Sakaida I. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: Is the addition of subcutaneous interferon-alpha-2b beneficial? Hepatol Res. 2009;39:223-230. [PMID: 19054152 DOI: 10.1111/j.1872-034x.2008.00458.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
40 Azad A, Chionh F, Cebon J. Targeted agents for the systemic treatment of advanced hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology 2009;5:76-86. [DOI: 10.1111/j.1743-7563.2009.01202.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
41 Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther. 2001;15:689-698. [PMID: 11328263 DOI: 10.1046/j.1365-2036.2001.00979.x] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 4.5] [Reference Citation Analysis]
42 Tella SH, Mahipal A, Kommalapati A, Jin Z. Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date. Onco Targets Ther. 2019;12:10335-10342. [PMID: 31819517 DOI: 10.2147/ott.s214870] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
43 Perry JF, Strasser SI, George J, Farrell GC, Mccaughan GW. Pharmacotherapy of hepatocellular carcinoma. Expert Opinion on Pharmacotherapy 2005;4:2175-85. [DOI: 10.1517/14656566.4.12.2175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
44 Vera MC, Lucci A, Ferretti AC, Abbondanzieri AA, Comanzo CG, Lorenzetti F, Pisani GB, Ceballos MP, Alvarez ML, Carrillo MC, Quiroga AD. The chemoprotective effects of IFN-α-2b on rat hepatocarcinogenesis are blocked by vitamin E supplementation. J Nutr Biochem 2021;96:108806. [PMID: 34147603 DOI: 10.1016/j.jnutbio.2021.108806] [Reference Citation Analysis]
45 Alvarez MDL, Quiroga AD, Ronco MT, Parody JP, Ochoa JE, Monti JA, Carnovale CE, Carrillo MC. Time-dependent onset of Interferon-α2b-induced apoptosis in isolated hepatocytes from preneoplastic rat livers. Cytokine 2006;36:245-53. [DOI: 10.1016/j.cyto.2007.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
46 Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut. 2003;52 Suppl 3:iii1-iii8. [PMID: 12692148 DOI: 10.1136/gut.52.suppl_3.iii1] [Cited by in Crossref: 132] [Cited by in F6Publishing: 176] [Article Influence: 6.9] [Reference Citation Analysis]
47 O’Suilleabhain CB, Poon RT, Yong JL, Ooi GC, Tso WK, Fan ST. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg. 2003;90:325-331. [PMID: 12594668 DOI: 10.1002/bjs.4045] [Cited by in Crossref: 80] [Cited by in F6Publishing: 82] [Article Influence: 4.2] [Reference Citation Analysis]
48 Uka K, Aikata H, Takaki S, Miki D, Jeong SC, Hiramatsu A, Kodama H, Shirakawa H, Kawakami Y, Takahashi S, Toyota N, Ito K, Chayama K. Similar effects of recombinant interferon-?-2b and natural interferon-? when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. Liver Int 2007;0:070908015728003-???. [DOI: 10.1111/j.1478-3231.2007.01554.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.1] [Reference Citation Analysis]
49 Gans JH, Lipman J, Golowa Y, Kinkhabwala M, Kaubisch A. Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in? Seminars in Nuclear Medicine 2019;49:170-81. [DOI: 10.1053/j.semnuclmed.2019.01.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
50 Cao J, Kong FH, Liu X, Wang XB. Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: A meta-analysis. World J Gastroenterol 2019; 25(27): 3649-3663 [PMID: 31367163 DOI: 10.3748/wjg.v25.i27.3649] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
51 Yuen MF, Ooi CG, Hui CK, Wong WM, Wong BC, Chan AO, Lai CL. A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma. Cancer 2003;97:2776-82. [PMID: 12767090 DOI: 10.1002/cncr.11400] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
52 Yau T, Chan P, Epstein R, Poon RT. Evolution of systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol 2008; 14(42): 6437-6441 [PMID: 19030192 DOI: 10.3748/wjg.14.6437] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
53 Salah RA, Nasr MA, El-Derby AM, Abd Elkodous M, Mohamed RH, El-Ekiaby N, Osama A, Elshenawy SE, Hamad MHM, Magdeldin S, Gabr MM, Abdelaziz AI, El-Badri NS. Hepatocellular carcinoma cell line-microenvironment induced cancer-associated phenotype, genotype and functionality in mesenchymal stem cells. Life Sci 2022;288:120168. [PMID: 34826437 DOI: 10.1016/j.lfs.2021.120168] [Reference Citation Analysis]
54 Vogl TJ, Naguib NN, Nour-eldin NA, Rao P, Emami AH, Zangos S, Nabil M, Abdelkader A. Review on transarterial chemoembolization in hepatocellular carcinoma: Palliative, combined, neoadjuvant, bridging, and symptomatic indications. European Journal of Radiology 2009;72:505-16. [DOI: 10.1016/j.ejrad.2008.08.007] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 6.5] [Reference Citation Analysis]
55 Floudas CS, Brar G, Greten TF. Immunotherapy: Current Status and Future Perspectives. Dig Dis Sci 2019;64:1030-40. [DOI: 10.1007/s10620-019-05516-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
56 Zamor PJ, deLemos AS, Russo MW. Viral hepatitis and hepatocellular carcinoma: etiology and management. J Gastrointest Oncol 2017;8:229-42. [PMID: 28480063 DOI: 10.21037/jgo.2017.03.14] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 12.0] [Reference Citation Analysis]
57 Damdinsuren B, Nagano H, Monden M. Combined intra-arterial 5-fluorouracil and subcutaneous interferon-alpha therapy for highly advanced hepatocellular carcinoma. Hepatol Res 2007;37 Suppl 2:S238-50. [PMID: 17877489 DOI: 10.1111/j.1872-034X.2007.00191.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
58 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 45.0] [Reference Citation Analysis]
59 Montella L, Sarno F, Ambrosino A, Facchini S, D'Antò M, Laterza MM, Fasano M, Quarata E, Ranucci RAN, Altucci L, Berretta M, Facchini G. The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma. Cells 2021;10:1909. [PMID: 34440678 DOI: 10.3390/cells10081909] [Reference Citation Analysis]
60 Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J, EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430. [PMID: 11592607 DOI: 10.1016/s0168-8278(01)00130-1] [Cited by in Crossref: 3112] [Cited by in F6Publishing: 1064] [Article Influence: 155.6] [Reference Citation Analysis]
61 Vilarinho S, Taddei T. Therapeutic strategies for hepatocellular carcinoma: new advances and challenges. Curr Treat Options Gastroenterol 2015;13:219-34. [PMID: 25791207 DOI: 10.1007/s11938-015-0049-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
62 Damdinsuren B, Nagano H, Wada H, Noda T, Natsag J, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Doki Y, Dono K, Monden M. Interferon alpha receptors are important for antiproliferative effect of interferon-alpha against human hepatocellular carcinoma cells. Hepatol Res 2007;37:77-83. [PMID: 17300701 DOI: 10.1111/j.1872-034X.2007.00007.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
63 Arakawa Y, Shimada M, Utsunomiya T, Imura S, Morine Y, Ikemoto T. Effects of pegylated interferon α2b on metastasis of hepatocellular carcinoma. J Surg Res 2012;172:95-101. [PMID: 20851413 DOI: 10.1016/j.jss.2010.07.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
64 Evdokimova VN, Butterfield LH. Alpha-fetoprotein and other tumour-associated antigens for immunotherapy of hepatocellular cancer. Expert Opin Biol Ther 2008;8:325-36. [PMID: 18294103 DOI: 10.1517/14712598.8.3.325] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
65 Tang ZY. Hepatocellular Carcinoma-Cause, Treatment and Metastasis. World J Gastroenterol 2001; 7(4): 445-454 [PMID: 11819809 DOI: 10.3748/wjg.v7.i4.445] [Cited by in CrossRef: 277] [Cited by in F6Publishing: 269] [Article Influence: 13.2] [Reference Citation Analysis]
66 Nishikawa H, Osaki Y, Kita R, Kimura T. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan. Cancers (Basel) 2012;4:165-83. [PMID: 24213234 DOI: 10.3390/cancers4010165] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
67 Robinson MK, Weiner LM, Adams GP. Improving mono-clonal antibodies for cancer therapy. Drug Development Res. 2004;61:172-187. [PMID: 11819809 DOI: 10.1002/ddr.10345] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
68 Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Müllhaupt B, Clavien PA. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg. 2009;96:975-981. [PMID: 19672926 DOI: 10.1002/bjs.6731] [Cited by in Crossref: 108] [Cited by in F6Publishing: 106] [Article Influence: 8.3] [Reference Citation Analysis]
69 Wang L, Jia D, Duan F, Sun Z, Liu X, Zhou L, Sun L, Ren S, Ruan Y, Gu J. Combined anti-tumor effects of IFN-α and sorafenib on hepatocellular carcinoma in vitro and in vivo. Biochem Biophys Res Commun. 2012;422:687-692. [PMID: 22634008 DOI: 10.1016/j.bbrc.2012.05.056] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
70 Brown ZJ, Greten TF. Immune Therapies. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 239-53. [DOI: 10.1007/978-3-030-21540-8_12] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
71 Chokshi MM, Marrero JA. Hepatocellular carcinoma. Curr Opin Gastroenterol 2001;17:276-80. [PMID: 17031169 DOI: 10.1097/00001574-200105000-00011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
72 Gao XM, Zhu Y, Li JH, Wang XY, Zhang XF, Yi CH, Yang X. microRNA-26a induces a mitochondrial apoptosis mediated by p53 through targeting to inhibit Mcl1 in human hepatocellular carcinoma. Onco Targets Ther 2018;11:2227-39. [PMID: 29719405 DOI: 10.2147/OTT.S160895] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
73 Zhao Y, Li H, Bai W, Liu J, Lv W, Sahu S, Guan S, Qin X, Wang W, Ren W. Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients. Int J Cancer. 2016;139:928-937. [PMID: 27038145 DOI: 10.1002/ijc.30124] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
74 Sangro B, Palmer D, Melero I. Immunotherapy of hepatocellular carcinoma. Hepat Oncol 2014;1:433-46. [PMID: 30190978 DOI: 10.2217/hep.14.16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
75 Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010;51:1274-1283. [PMID: 20112254 DOI: 10.1002/hep.23485] [Cited by in Crossref: 249] [Cited by in F6Publishing: 230] [Article Influence: 20.8] [Reference Citation Analysis]
76 Greten TF, Manns MP, Korangy F. Immunotherapy of hepatocellular carcinoma. J Hepatol. 2006;45:868-878. [PMID: 17046096 DOI: 10.1016/j.jhep.2006.09.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
77 Brar G, Greten TF, Brown ZJ. Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy. Therap Adv Gastroenterol 2018;11:1756284818808086. [PMID: 30377451 DOI: 10.1177/1756284818808086] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
78 Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, Ge YS. Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials. Int J Cancer. 2011;129:1254-1264. [PMID: 21710498 DOI: 10.1002/ijc.25767] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.5] [Reference Citation Analysis]
79 Reig M, Gazzola A, Di Donato R, Bruix J. Systemic treatment. Best Practice & Research Clinical Gastroenterology 2014;28:921-35. [DOI: 10.1016/j.bpg.2014.08.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
80 Ahn J, Flamm SL. Hepatocellular carcinoma. Dis Mon 2004;50:556-73. [PMID: 15616490 DOI: 10.1016/j.disamonth.2004.10.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
81 Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, Kawata S, Imai Y, Iijima S, Monden M. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer. 2002;94:435-442. [PMID: 11900229 DOI: 10.1002/cncr.10246] [Cited by in Crossref: 147] [Cited by in F6Publishing: 129] [Article Influence: 7.4] [Reference Citation Analysis]
82 Müller C. Hepatocellular carcinoma – Rising incidence, changing therapeutic strategies. Wien Med Wochenschr 2006;156:404-9. [DOI: 10.1007/s10354-006-0316-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
83 Wáng YX, De Baere T, Idée JM, Ballet S. Transcatheter embolization therapy in liver cancer: an update of clinical evidences. Chin J Cancer Res 2015;27:96-121. [PMID: 25937772 DOI: 10.3978/j.issn.1000-9604.2015.03.03] [Cited by in F6Publishing: 34] [Reference Citation Analysis]
84 Tian M, Shi Y, Liu W, Fan J. Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention. Sci China Life Sci 2019;62:1138-43. [PMID: 31119560 DOI: 10.1007/s11427-018-9446-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
85 Garcea G, Lloyd TD, Aylott C, Maddern G, Berry DP. The emergent role of focal liver ablation techniques in the treatment of primary and secondary liver tumours. Eur J Cancer 2003;39:2150-64. [PMID: 14522372 DOI: 10.1016/s0959-8049(03)00553-7] [Cited by in Crossref: 68] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
86 Zhu AX. Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be? The Oncologist 2006;11:790-800. [DOI: 10.1634/theoncologist.11-7-790] [Cited by in Crossref: 181] [Cited by in F6Publishing: 172] [Article Influence: 11.3] [Reference Citation Analysis]
87 Yamamoto A, Sato T. Locoregional treatment of malignant hepatic tumors with biologic response modifiers. Surg Oncol Clin N Am 2008;17:935-55, xii. [PMID: 18722927 DOI: 10.1016/j.soc.2008.04.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Weis S, Franke A, Berg T, Mössner J, Fleig WE, Schoppmeyer K. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev 2015;1:CD006745. [PMID: 25620061 DOI: 10.1002/14651858.CD006745.pub3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
89 Harding JJ, El Dika I, Abou-Alfa GK. Immunotherapy in hepatocellular carcinoma: Primed to make a difference? Cancer. 2016;122:367-377. [PMID: 26540029 DOI: 10.1002/cncr.29769] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 11.1] [Reference Citation Analysis]
90 Chaparro M, González Moreno L, Trapero-Marugán M, Medina J, Moreno-Otero R. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. Aliment Pharmacol Ther 2008;28:1269-77. [PMID: 18808443 DOI: 10.1111/j.1365-2036.2008.03857.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
91 Schoppmeyer K, Weis S, Mössner J, Fleig WE. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev. 2009;3:CD006745. [PMID: 19588401 DOI: 10.1002/14651858.cd006745.pub2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
92 Roxburgh P, Evans TR. Systemic therapy of hepatocellular carcinoma: are we making progress? Adv Ther. 2008;25:1089-1104. [PMID: 18972075 DOI: 10.1007/s12325-008-0113-z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
93 Llovet JM, Bruix J. Early diagnosis and treatment of hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol 2000;14:991-1008. [PMID: 11139351 DOI: 10.1053/bega.2000.0143] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 1.6] [Reference Citation Analysis]
94 Roth GS, Decaens T. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives. Eur J Cancer 2017;87:101-12. [PMID: 29145036 DOI: 10.1016/j.ejca.2017.10.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
95 Palmer DH, Hussain SA, Johnson PJ. Gene- and immunotherapy for hepatocellular carcinoma. Expert Opin Biol Ther. 2005;5:507-523. [PMID: 15934829 DOI: 10.1517/14712598.5.4.507] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
96 Borie F, Bouvier AM, Herrero A, Faivre J, Launoy G, Delafosse P, Velten M, Buemi A, Peng J, Grosclaude P, Trétarre B. Treatment and prognosis of hepatocellular carcinoma: a population based study in France. J Surg Oncol 2008;98:505-9. [PMID: 18932235 DOI: 10.1002/jso.21159] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 4.0] [Reference Citation Analysis]
97 Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. Journal of Hepatology 2003;38:136-49. [DOI: 10.1016/s0168-8278(02)00432-4] [Cited by in Crossref: 156] [Cited by in F6Publishing: 56] [Article Influence: 8.2] [Reference Citation Analysis]
98 Nakamura M, Nagano H, Marubashi S, Miyamoto A, Takeda Y, Kobayashi S, Wada H, Noda T, Dono K, Umeshita K, Monden M. Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis. Cancer 2008;112:1765-71. [PMID: 18327806 DOI: 10.1002/cncr.23356] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
99 Zhang YF, Shi M, Lu LH, Wang L, Guo RP. Selecting an Optimal Staging System for Intermediate-Stage Hepatocellular Carcinoma: Comparison of 9 Currently Used Prognostic Models. J Hepatocell Carcinoma 2021;8:253-61. [PMID: 33907695 DOI: 10.2147/JHC.S305581] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002;235:466-86. [PMID: 11923602 DOI: 10.1097/00000658-200204000-00004] [Cited by in Crossref: 300] [Cited by in F6Publishing: 283] [Article Influence: 15.0] [Reference Citation Analysis]
101 Rougier P, Mitry E, Barbare JC, Taieb J. Hepatocellular carcinoma (HCC): an update. Semin Oncol. 2007;34:S12-S20. [PMID: 17449346 DOI: 10.1053/j.seminoncol.2007.01.007] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 2.6] [Reference Citation Analysis]
102 Obora A, Shiratori Y, Okuno M, Adachi S, Takano Y, Matsushima-Nishiwaki R, Yasuda I, Yamada Y, Akita K, Sano T. Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells. Hepatology. 2002;36:1115-1124. [PMID: 12395321 DOI: 10.1053/jhep.2002.36369] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
103 Crespo J, San Miguel G, García Pajares F, Castro B, Pons Romero F. ¿Por qué no reciben tratamiento todos los pacientes con una hepatopatía crónica relacionada con el virus de la hepatitis C? Gastroenterología y Hepatología 2001;24:181-5. [DOI: 10.1016/s0210-5705(01)70145-8] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
104 El-ayouty Y, El-manawy I, Nasih S, Hamdy E, Kebeish R. Engineering Chlamydomonas reinhardtii for Expression of Functionally Active Human Interferon-α. Mol Biotechnol 2019;61:134-44. [DOI: 10.1007/s12033-018-0143-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
105 Beaugrand M, Trinchet JC. [Non-surgical treatment of hepatocellular carcinoma. An overview]. Cancer Radiother 2005;9:464-9. [PMID: 16236541 DOI: 10.1016/j.canrad.2005.09.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
106 Spangenberg HC, Thimme R, Blum HE. Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009;6:423-32. [DOI: 10.1038/nrgastro.2009.86] [Cited by in Crossref: 80] [Cited by in F6Publishing: 81] [Article Influence: 6.2] [Reference Citation Analysis]
107 Donckier V, Van Laethem JL, Van Gansbeke D, Ickx B, Lingier P, Closset J, El Nakadi I, Feron P, Boon N, Bourgeois N, Adler M, Gelin M. New considerations for an overall approach to treat hepatocellular carcinoma in cirrhotic patients. J Surg Oncol 2003;84:36-44. [DOI: 10.1002/jso.10281] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
108 Fitzmorris P, Shoreibah M, Anand BS, Singal AK. Management of hepatocellular carcinoma. J Cancer Res Clin Oncol 2015;141:861-76. [DOI: 10.1007/s00432-014-1806-0] [Cited by in Crossref: 59] [Cited by in F6Publishing: 67] [Article Influence: 7.4] [Reference Citation Analysis]
109 Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. The Lancet 2003;362:1907-17. [DOI: 10.1016/s0140-6736(03)14964-1] [Cited by in Crossref: 3076] [Cited by in F6Publishing: 1294] [Article Influence: 161.9] [Reference Citation Analysis]
110 Lewandowski RJ, Wang D, Gehl J, Atassi B, Ryu RK, Sato K, Nemcek AA Jr, Miller FH, Mulcahy MF, Kulik L, Larson AC, Salem R, Omary RA. A comparison of chemoembolization endpoints using angiographic versus transcatheter intraarterial perfusion/MR imaging monitoring. J Vasc Interv Radiol 2007;18:1249-57. [PMID: 17911515 DOI: 10.1016/j.jvir.2007.06.028] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 3.6] [Reference Citation Analysis]
111 Vogl TJ, Nour-Eldin NE, Emad-Eldin S, Naguib NN, Trojan J, Ackermann H, Abdelaziz O. Portal vein thrombosis and arterioportal shunts: Effects on tumor response after chemoembolization of hepatocellular carcinoma. World J Gastroenterol 2011; 17(10): 1267-1275 [PMID: 21455325 DOI: 10.3748/wjg.v17.i10.1267] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
112 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Gao Q, Shi Y, Wang X, Zhou J, Qiu S, Fan J. Translational medicine in hepatocellular carcinoma. Front Med. 2012;6:122-133. [PMID: 22573220 DOI: 10.1007/s11684-012-0193-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
114 El Dika I, Makki I, Abou-Alfa GK. Hepatocellular carcinoma, novel therapies on the horizon. Chin Clin Oncol 2021;10:12. [PMID: 32527116 DOI: 10.21037/cco-20-113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
115 Nasrollahzadeh Sabet M, Movahedi Asl M, Kazemi Esfeh M, Nasrabadi N, Shakarami M, Alani B, Alimolaie A, Azhdari S, Cheraghi E. Mesenchymal stem cells as professional actors in gastrointestinal cancer therapy: From Naïve to genetically modified. Iran J Basic Med Sci 2021;24:561-76. [PMID: 34249257 DOI: 10.22038/ijbms.2021.54735.12277] [Reference Citation Analysis]
116 Verset G, Verslype C, Reynaert H, Borbath I, Langlet P, Vandebroek A, Peeters M, Houbiers G, Francque S, Arvanitakis M. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer. 2007;97:582-588. [PMID: 17687341 DOI: 10.1038/sj.bjc.6603901] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
117 El-serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and Treatment of Hepatocellular Carcinoma. Gastroenterology 2008;134:1752-63. [DOI: 10.1053/j.gastro.2008.02.090] [Cited by in Crossref: 690] [Cited by in F6Publishing: 649] [Article Influence: 49.3] [Reference Citation Analysis]
118 Wrzesinski SH, Taddei TH, Strazzabosco M. Systemic therapy in hepatocellular carcinoma. Clin Liver Dis 2011;15:423-41, vii-x. [PMID: 21689622 DOI: 10.1016/j.cld.2011.03.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
119 Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer. 2004;40:1474-1484. [PMID: 15196530 DOI: 10.1016/j.ejca.2004.02.027] [Cited by in Crossref: 134] [Cited by in F6Publishing: 114] [Article Influence: 7.4] [Reference Citation Analysis]
120 Prieto J, Qian C, Sangro B, Melero I, Mazzolini G. Biologic therapy of liver tumors. Surg Clin North Am. 2004;84:673-696. [PMID: 15062668 DOI: 10.1016/s0039-6109(03)00230-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
121 Clavien PA. Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection? Ann Surg. 2007;245:843-845. [PMID: 17522507 DOI: 10.1097/sla.0b013e31805d0788] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
122 Procaccio L, Schirripa M, Fassan M, Vecchione L, Bergamo F, Prete AA, Intini R, Manai C, Dadduzio V, Boscolo A. Immunotherapy in Gastrointestinal Cancers. Biomed Res Int. 2017;2017:4346576. [PMID: 28758114 DOI: 10.1155/2017/4346576] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
123 Hisaka T, Yano H, Ogasawara S, Momosaki S, Nishida N, Takemoto Y, Kojiro S, Katafuchi Y, Kojiro M. Interferon-alphaCon1 suppresses proliferation of liver cancer cell lines in vitro and in vivo. J Hepatol. 2004;41:782-789. [PMID: 15519651 DOI: 10.1016/j.jhep.2004.07.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
124 Merle P, Mornex F. [Medical therapies for hepatocellular carcinoma]. Cancer Radiother 2011;15:28-31. [PMID: 21237692 DOI: 10.1016/j.canrad.2010.12.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
125 Lai E, Astara G, Ziranu P, Pretta A, Migliari M, Dubois M, Donisi C, Mariani S, Liscia N, Impera V, Persano M, Tolu S, Balconi F, Pinna G, Spanu D, Pireddu A, Saba G, Camera S, Musio F, Puzzoni M, Pusceddu V, Madeddu C, Casadei Gardini A, Scartozzi M. Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? Crit Rev Oncol Hematol. 2021;157:103167. [PMID: 33271389 DOI: 10.1016/j.critrevonc.2020.103167] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
126 Lasfar A, Abushahba W, Balan M, Cohen-Solal KA. Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol 2011;2011:349575. [PMID: 22190970 DOI: 10.1155/2011/349575] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
127 Mahipal A, Tella SH, Kommalapati A, Lim A, Kim R. Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel? Cancers (Basel) 2019;11:E1078. [PMID: 31366113 DOI: 10.3390/cancers11081078] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
128 Hernandez-Alcoceba R, Sangro B, Berraondo P, Gonzalez-Aseguinolaza G, Prieto J. Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives. Expert Opin Investig Drugs 2013;22:827-41. [PMID: 23594171 DOI: 10.1517/13543784.2013.793307] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
129 Spangenberg HC, Thimme R, Von Weizsäcker F, Blum HE. [Best supportive care of hepatocellular carcinoma]. Internist (Berl) 2004;45:777-85. [PMID: 15160245 DOI: 10.1007/s00108-004-1226-3] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
130 Tawada A, Kanda T, Imazeki F, Yokosuka O. Prevention of hepatitis B virus-associated liver diseases by antiviral therapy. Hepatol Int 2016;10:574-93. [PMID: 27026375 DOI: 10.1007/s12072-016-9720-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
131 Tsuchiya N, Sawada Y, Endo I, Uemura Y, Nakatsura T. Potentiality of immunotherapy against hepatocellular carcinoma. World J Gastroenterol 2015; 21(36): 10314-10326 [PMID: 26420958 DOI: 10.3748/wjg.v21.i36.10314] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
132 Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002;95:588-595. [PMID: 12209752 DOI: 10.1002/cncr.10694] [Cited by in Crossref: 233] [Cited by in F6Publishing: 214] [Article Influence: 11.7] [Reference Citation Analysis]
133 Kim RD, Reed AI, Fujita S, Foley DP, Mekeel KL, Hemming AW. Consensus and controversy in the management of hepatocellular carcinoma. J Am Coll Surg. 2007;205:108-123. [PMID: 17617340 DOI: 10.1016/j.jamcollsurg.2007.02.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
134 Zhu AX. Hepatocellular carcinoma: are we making progress? Cancer Invest. 2003;21:418-428. [PMID: 12901288 DOI: 10.1081/cnv-120018233] [Cited by in Crossref: 45] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
135 Forner A, Hessheimer AJ, Isabel Real M, Bruix J. Treatment of hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2006;60:89-98. [DOI: 10.1016/j.critrevonc.2006.06.001] [Cited by in Crossref: 104] [Cited by in F6Publishing: 95] [Article Influence: 6.5] [Reference Citation Analysis]
136 Maida M, Cabibbo G, Brancatelli G, Genco C, Alessi N, Genova C, Romano P, Raineri M, Giarratano A, Midiri M. Assessment of treatment response in hepatocellular carcinoma: a review of the literature. Future Oncol. 2013;9:845-854. [PMID: 23718305 DOI: 10.2217/fon.13.33] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
137 Cristina Carrillo M, de Luján Álvarez M, Darío Quiroga A. Interferon alfa-2b triggers transforming growth factor-β1-induced apoptosis on preneoplastic liver. Annals of Hepatology 2006;5:244-50. [DOI: 10.1016/s1665-2681(19)31982-9] [Cited by in Crossref: 8] [Article Influence: 0.5] [Reference Citation Analysis]
138 Nakamura M, Nagano H, Sakon M, Yamamoto T, Ota H, Wada H, Damdinsuren B, Noda T, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Nakamori S, Dono K, Monden M. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. J Hepatol 2007;46:77-88. [PMID: 17045692 DOI: 10.1016/j.jhep.2006.07.032] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 3.1] [Reference Citation Analysis]
139 Matar P, Alaniz L, Rozados V, Aquino JB, Malvicini M, Atorrasagasti C, Gidekel M, Silva M, Scharovsky OG, Mazzolini G. Immunotherapy for liver tumors: present status and future prospects. J Biomed Sci. 2009;16:30. [PMID: 19272130 DOI: 10.1186/1423-0127-16-30] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
140 Butterfield LH, Ribas A. Immunotherapy of hepatocellular carcinoma. Expert Opin Biol Ther. 2002;2:123-133. [PMID: 11849113 DOI: 10.1517/14712598.2.2.123] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
141 Galandi D, Antes G. Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma. Cochrane Database Syst Rev. 2004;CD003046. [PMID: 15106188 DOI: 10.1002/14651858.cd003046.pub3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 38] [Article Influence: 1.7] [Reference Citation Analysis]
142 Alsowmely AM, Hodgson HJ. Non-surgical treatment of hepatocellular carcinoma. Aliment Pharmacol Ther. 2002;16:1-15. [PMID: 11856073 DOI: 10.1046/j.1365-2036.2002.01149.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
143 Sherman M. Primary Malignant Neoplasms of the Liver. In: Dooley JS, Lok ASF, Burroughs AK, Heathcote EJ, editors. Sherlock's Diseases of the Liver and Biliary System. Oxford: Wiley-Blackwell; 2011. pp. 681-703. [DOI: 10.1002/9781444341294.ch35] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
144 Okuno M, Kojima S, Moriwaki H. Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives. J Gastroenterol Hepatol. 2001;16:1329-1335. [PMID: 11851828 DOI: 10.1046/j.1440-1746.2001.02634.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
145 Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, Tateishi R, Teratani T, Shiina S, Omata M. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2006;106:1990-1997. [PMID: 16565970 DOI: 10.1002/cncr.21832] [Cited by in Crossref: 194] [Cited by in F6Publishing: 182] [Article Influence: 12.1] [Reference Citation Analysis]
146 Korean Liver Cancer Study Group and National Cancer Center, Korea. [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol. 2009;15:391-423. [PMID: 19783891 DOI: 10.3350/kjhep.2009.15.3.391] [Cited by in Crossref: 182] [Cited by in F6Publishing: 183] [Article Influence: 15.2] [Reference Citation Analysis]
147 Schlosser SF, Schuler M, Berg CP, Lauber K, Schulze-Osthoff K, Schmahl FW, Wesselborg S. Ribavirin and alpha interferon enhance death receptor-mediated apoptosis and caspase activation in human hepatoma cells. Antimicrob Agents Chemother 2003;47:1912-21. [PMID: 12760867 DOI: 10.1128/AAC.47.6.1912-1921.2003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
148 Johnson PJ. Systemic chemotherapy of liver tumors. Semin Surg Oncol 2000;19:116-24. [PMID: 11126376 DOI: 10.1002/1098-2388(200009)19:2<116::aid-ssu4>3.0.co;2-f] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
149 Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF. The yin and yang of evasion and immune activation in HCC. J Hepatol. 2015;62:1420-1429. [PMID: 25733155 DOI: 10.1016/j.jhep.2015.02.038] [Cited by in Crossref: 139] [Cited by in F6Publishing: 151] [Article Influence: 19.9] [Reference Citation Analysis]
150 Schwartz JD, Beutler AS. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials—II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma. Anti-Cancer Drugs 2004;15:439-52. [DOI: 10.1097/01.cad.0000131140.12228.bb] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
151 Bruix J, Sherman M;  Practice Guidelines Committee;  American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236. [PMID: 16250051 DOI: 10.1002/hep.20933] [Cited by in Crossref: 4104] [Cited by in F6Publishing: 3893] [Article Influence: 241.4] [Reference Citation Analysis]
152 Sun HC, Tang ZY. Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol. 2004;130:307-319. [PMID: 15034787 DOI: 10.1007/s00432-003-0530-y] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 3.7] [Reference Citation Analysis]
153 Chen LT, Chen MF, Li LA, Lee PH, Jeng LB, Lin DY, Wu CC, Mok KT, Chen CL, Lee WC, Chau GY, Chen YS, Lui WY, Hsiao CF, Whang-Peng J, Chen PJ; Disease Committee of Adjuvant Therapy for Postoperative Hepatocellular Carcinoma, Taiwan Cooperative Oncology Group, National Health Research Institutes, Zhunan, Taiwan. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg. 2012;255:8-17. [PMID: 22104564 DOI: 10.1097/sla.0b013e3182363ff9] [Cited by in Crossref: 78] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
154 Genco C, Cabibbo G, Maida M, Brancatelli G, Galia M, Alessi N, Butera G, Genova C, Romano P, Raineri M. Treatment of hepatocellular carcinoma: present and future. Expert Rev Anticancer Ther. 2013;13:469-479. [PMID: 23560841 DOI: 10.1586/era.13.21] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
155 Brown KS. Chemotherapy and other systemic therapies for hepatocellular carcinoma and liver metastases. Semin Intervent Radiol 2006;23:99-108. [PMID: 21326724 DOI: 10.1055/s-2006-939845] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
156 Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol. 2005;100:1995-2004. [PMID: 16128944 DOI: 10.1111/j.1572-0241.2005.00229.x] [Cited by in Crossref: 100] [Cited by in F6Publishing: 95] [Article Influence: 5.9] [Reference Citation Analysis]
157 Giglia JL, Antonia SJ, Berk LB, Bruno S, Dessureault S, Finkelstein SE. Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. Cancer Control 2010;17:120-9. [PMID: 20404795 DOI: 10.1177/107327481001700207] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
158 Nagano H, Miyamoto A, Wada H, Ota H, Marubashi S, Takeda Y, Dono K, Umeshita K, Sakon M, Monden M. Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer. 2007;110:2493-2501. [PMID: 17941012 DOI: 10.1002/cncr.23033] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]
159 Abushahba W, Balan M, Castaneda I, Yuan Y, Reuhl K, Raveche E, de la Torre A, Lasfar A, Kotenko SV. Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother 2010;59:1059-71. [PMID: 20217081 DOI: 10.1007/s00262-010-0831-3] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 5.6] [Reference Citation Analysis]
160 Weis S, Franke A, Berg T, Mössner J, Fleig WE, Schoppmeyer K. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev 2015;1:CD006745. [PMID: 25620061 DOI: 10.1002/14651858.CD006745.pub3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
161 Elkhenany H, Shekshek A, Abdel-Daim M, El-Badri N. Stem Cell Therapy for Hepatocellular Carcinoma: Future Perspectives. Adv Exp Med Biol 2020;1237:97-119. [PMID: 31728916 DOI: 10.1007/5584_2019_441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
162 Rui JA, Wang SB, Chen SG, Zhou L. Right trisectionectomy for primary liver cancer. World J Gastroenterol 2003; 9(4): 706-709 [PMID: 12679915 DOI: 10.3748/wjg.v9.i4.706] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
163 Yegin EG, Oymaci E, Karatay E, Coker A. Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment. Hepatobiliary & Pancreatic Diseases International 2016;15:234-56. [DOI: 10.1016/s1499-3872(16)60097-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
164 Taieb J, Barbare J, Rougier P. Medical treatments for hepatocellular carcinoma (HCC): what’s next? Annals of Oncology 2006;17:x308-14. [DOI: 10.1093/annonc/mdl279] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
165 Komorizono Y, Kohara K, Oketani M, Maeda M, Shibathou T, Shigenobu S, Hiramine Y, Yamasaki N, Arima T, Kazuaki I, Arima T. Systemic combined chemotherapy with low dose of 5-fluorouracil, cisplatin, and interferon-alpha for advanced hepatocellular carcinoma: a pilot study. Dig Dis Sci 2003;48:877-81. [PMID: 12772783 DOI: 10.1023/a:1023035109665] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
166 Tam KH, Yang ZF, Lau CK, Lam CT, Pang RW, Poon RT. Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. Cancer Lett 2009;273:201-9. [PMID: 18824293 DOI: 10.1016/j.canlet.2008.08.018] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]